Bixiye
P68-22 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama
Taariikhda uu dhaqangalayo Barnaamijka: Nov 01, 2022
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 1831 - 1840 ee natiijooyinka 3167
Bixiye
P71-22 Reimbursement Policy Changes for Minnesota Health Care Programs
Taariikhda uu dhaqangalayo Barnaamijka: Nov 01, 2022
Bixiye
P66-22 eviCore Healthcare Specialty Utilization Management (UM) Program: Medical Oncology Drug Prior Authorization Updates
Taariikhda uu dhaqangalayo Barnaamijka: Nov 01, 2022
Bixiye
QP89-22 Provider Press: Q3 2022
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP87-22 MHCP Pharmacy Benefit Update: New drug-related Prior Authorization (PA) Criteria: Strensiq® (asfotase alfa)
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP86-22 MHCP Pharmacy Benefit Update: New drug-related Prior Authorization (PA) Criteria: Vtama® (tapinarof)
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP84-22 MHCP Pharmacy Benefit Update: New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Camzyos™ (mavacamten)
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP85-22 MHCP Pharmacy Benefit Update: New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Radicava® (edaravone)
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP88-22 Provider Press: Q2 2022
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP83-22 MHCP Pharmacy Benefit Exclusion for Somatuline® Depot and Sandostatin® LAR Depot
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022